Dual affinity fusion approach and its use to express recombinant human insulin-like growth factor II
- PMID: 2543972
- PMCID: PMC287270
- DOI: 10.1073/pnas.86.12.4367
Dual affinity fusion approach and its use to express recombinant human insulin-like growth factor II
Abstract
A dual affinity fusion concept has been developed in which the gene encoding the desired product is fused between two flanking heterologous genes encoding IgG- and albumin-binding domains. Using sequential IgG and serum albumin affinity chromatography, a full-length tripartite fusion protein is obtained. This approach was used to recover a full-length fusion product in Escherichia coli containing the human insulin-like growth factor II (IGF-II). Surprisingly, the recombinant IGF-II showed increased stability against proteolytic degradation in E. coli when produced as a dual affinity fusion protein, as compared to an N-terminal fusion protein. After site-specific cleavage of the tripartite fusion protein, IGF-II molecules with immunological and receptor binding activity were obtained without renaturation steps. The results demonstrate that proteins can fold into biologically active structures, even if provided with large flanking heterologous protein domains. The concept was further used to characterize the specific degradation of recombinant IGF-II in this heterologous host.
Similar articles
-
Production of biologically active recombinant tilapia insulin-like growth factor-II polypeptides in Escherichia coli cells and characterization of the genomic structure of the coding region.DNA Cell Biol. 1997 Jul;16(7):883-92. doi: 10.1089/dna.1997.16.883. DNA Cell Biol. 1997. PMID: 9260931
-
Hyperproduction of polyhedrin-IGF II fusion protein in silkworm larvae infected with recombinant Bombyx mori nuclear polyhedrosis virus.J Gen Virol. 1987 Oct;68 ( Pt 10):2599-606. doi: 10.1099/0022-1317-68-10-2599. J Gen Virol. 1987. PMID: 3312489
-
Molecular aspects of insulin-like growth factors, their binding proteins and receptors.Baillieres Clin Endocrinol Metab. 1988 Nov;2(4):1069-85. doi: 10.1016/s0950-351x(88)80030-2. Baillieres Clin Endocrinol Metab. 1988. PMID: 2855823 Review.
-
Differential stability of recombinant human insulin-like growth factor II in Escherichia coli and Staphylococcus aureus.J Biotechnol. 1990 Jun;14(3-4):423-37. doi: 10.1016/0168-1656(90)90123-s. J Biotechnol. 1990. PMID: 1366914
-
High-level expression of human insulin-like growth factor II in Escherichia coli.J Biotechnol. 1990 Mar;13(4):293-304. doi: 10.1016/0168-1656(90)90077-o. J Biotechnol. 1990. PMID: 1366560
Cited by
-
Simplified cloning and isolation of peptides from "sandwiched" SUMO-peptide-intein fusion proteins.BMC Biotechnol. 2023 Apr 5;23(1):11. doi: 10.1186/s12896-023-00779-5. BMC Biotechnol. 2023. PMID: 37020212 Free PMC article.
-
A Novel Tandem-Tag Purification Strategy for Challenging Disordered Proteins.Biomolecules. 2022 Oct 26;12(11):1566. doi: 10.3390/biom12111566. Biomolecules. 2022. PMID: 36358915 Free PMC article.
-
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo.MAbs. 2021 Jan-Dec;13(1):1893888. doi: 10.1080/19420862.2021.1893888. MAbs. 2021. PMID: 33691596 Free PMC article.
-
Sandwiched-fusion strategy facilitates recombinant production of small labile proteins.Protein Sci. 2021 Mar;30(3):650-662. doi: 10.1002/pro.4024. Epub 2021 Jan 29. Protein Sci. 2021. PMID: 33433908 Free PMC article.
-
Recent trends in protein and peptide-based biomaterials for advanced drug delivery.Adv Drug Deliv Rev. 2020;156:133-187. doi: 10.1016/j.addr.2020.08.008. Epub 2020 Aug 29. Adv Drug Deliv Rev. 2020. PMID: 32871201 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical